Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 2/20 | 0.62 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.62 |
| ▸ | ABL1 | P00519 | 1/20 | 0.62 |
| ▸ | RET | P07949 | 1/20 | 0.62 |
| ▸ | FLT3 | P36888 | 1/20 | 0.62 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.62 |
| ▸ | GRK5 | P34947 | 16/20 | 0.57 |
| ▸ | PAK4 | O96013 | 1/20 | 0.51 |
| ▸ | EGFR | P00533 | 1/20 | 0.51 |
| ▸ | KDR | P35968 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16486531 | 1.00 | PDGFRB (0.62) | PDGFRBFGFR1ABL1RETFLT3 | |
| SCHEMBL16568627 | 1.00 | PDGFRB (0.62) | PDGFRBFGFR1ABL1RETFLT3 | |
| SCHEMBL16490721 | 1.00 | PDGFRB (0.62) | PDGFRBFGFR1ABL1RETFLT3 | |
| SCHEMBL16490724 | 1.00 | PDGFRB (0.62) | PDGFRBFGFR1ABL1RETFLT3 | |
| SCHEMBL16486440 | 0.95 | PDGFRB (0.62) | PDGFRBFGFR1ABL1RETFLT3 | |
| SCHEMBL16490719 | 0.95 | PDGFRB (0.62) | PDGFRBFGFR1ABL1RETFLT3 | |
| SCHEMBL16568041 | 0.95 | PDGFRB (0.62) | PDGFRBFGFR1ABL1RETFLT3 | |
| SCHEMBL16490700 | 0.94 | GRK5 (0.61) | PDGFRBFGFR1ABL1RETFLT3 | |
| SCHEMBL16486943 | 0.94 | GRK5 (0.61) | PDGFRBFGFR1ABL1RETFLT3 | |
| SCHEMBL16486361 | 0.94 | GRK5 (0.61) | PDGFRBFGFR1ABL1RETFLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9458463-B2 | Method for treatment of diabetes by a small molecule inhibitor for GRK5 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2016-10-04 | — | — | US | claimed |
| WO-2015022437-A1 | INDOLINONE DERIVATIVES AS GRK5 MODULATORS | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2015-02-19 | — | — | WO | claimed |
| US-9458463-B2 | Method for treatment of diabetes by a small molecule inhibitor for GRK5 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2016-10-04 | — | — | US | disclosed |
| US-20150079108-A1 | KINASES AS TARGETS FOR ANTI-DIABETIC THERAPY | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2015-03-19 | — | — | US | disclosed |
| WO-2015022437-A1 | INDOLINONE DERIVATIVES AS GRK5 MODULATORS | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2015-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150079108-A1 | KINASES AS TARGETS FOR ANTI-DIABETIC THERAPY | GCKR, GRK4, GRK5 | PDGFRB 1512/4885FGFR1 583/4885ABL1 1524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.